These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 18197157)

  • 41. Residual catatonic state following neuroleptic malignant syndrome.
    Caroff SN; Mann SC; Keck PE; Francis A
    J Clin Psychopharmacol; 2000 Apr; 20(2):257-9. PubMed ID: 10770467
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Catatonia as a risk factor for the development of neuroleptic malignant syndrome: report of a case following treatment with clozapine.
    Paparrigopoulos T; Tzavellas E; Ferentinos P; Mourikis I; Liappas J
    World J Biol Psychiatry; 2009; 10(1):70-3. PubMed ID: 19673089
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neuroleptic malignant syndrome or catatonia? Trying to solve the catatonic dilemma.
    Lang FU; Lang S; Becker T; Jäger M
    Psychopharmacology (Berl); 2015 Jan; 232(1):1-5. PubMed ID: 25407348
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neuroleptic malignant syndrome: further lessons from a case report.
    Casamassima F; Lattanzi L; Perlis RH; Litta A; Fui E; Bonuccelli U; Fricchione G; Cassano GB
    Psychosomatics; 2010; 51(4):349-54. PubMed ID: 20587766
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Catatonia and the neuroleptics: psychobiologic significance of remote and recent findings.
    Blumer D
    Compr Psychiatry; 1997; 38(4):193-201. PubMed ID: 9202876
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neuroleptic Malignant Syndrome.
    Pileggi DJ; Cook AM
    Ann Pharmacother; 2016 Nov; 50(11):973-981. PubMed ID: 27423483
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recurrent Idiopathic Catatonia: Implications beyond the Diagnostic and Statistical Manual of Mental Disorders 5th Edition.
    Caroff SN; Hurford I; Bleier HR; Gorton GE; Campbell EC
    Clin Psychopharmacol Neurosci; 2015 Aug; 13(2):218-21. PubMed ID: 26243853
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Acute catatonia: Questions, diagnosis and prognostics, and the place of atypical antipsychotics].
    Belaizi M; Yahia A; Mehssani J; Bouchikhi Idrissi ML; Bichra MZ
    Encephale; 2013 Jun; 39(3):224-31. PubMed ID: 23095594
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diagnostic and therapeutic challenges in neuroleptic malignant syndrome: a severe medical case.
    Brogna P; Colasuonno R; Di Michele F; Paterniti AM; Talamo A; Ribolsi M; Jannini TB; Siracusano A; Niolu C
    Riv Psichiatr; 2020; 55(4):236-239. PubMed ID: 32724236
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical risk factors for neuroleptic malignant syndrome.
    Berardi D; Dell'Atti M; Amore M; De Ronchi D; Ferrari G
    Hum Psychopharmacol; 2002 Mar; 17(2):99-102. PubMed ID: 12404699
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Differential diagnosis of malignant hyperthermia, febrile catatonia and neuroleptic malignant syndrome. A case comparison].
    Schröder J; Linge C; Wähner A
    Fortschr Neurol Psychiatr; 1988 Mar; 56(3):97-101. PubMed ID: 2896144
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Are catatonia and neuroleptic malignant syndrome related conditions?].
    Vesperini S; Papetti F; Pringuey D
    Encephale; 2010 Apr; 36(2):105-10. PubMed ID: 20434626
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Successful diagnosis and treatment of pulmonary aspergillosis-related malignant catatonia using propofol and quetiapine: A case report.
    Nomura K; Sakawaki S; Sakawaki E; Yamaoka A; Aisaka W; Okamoto H; Takeyama Y; Uemura S; Narimatsu E
    Medicine (Baltimore); 2021 May; 100(19):e25967. PubMed ID: 34106671
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome and their association with death.
    Tural U; Onder E
    Psychiatry Clin Neurosci; 2010 Feb; 64(1):79-87. PubMed ID: 20416027
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular hypotheses to explain the shared pathways and underlying pathobiological causes in catatonia and in catatonic presentations in neuropsychiatric disorders.
    Peter-Ross EM
    Med Hypotheses; 2018 Apr; 113():54-64. PubMed ID: 29523295
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neuroleptic malignant syndrome: risk factors, pathophysiology, and treatment.
    Ananth J; Aduri K; Parameswaran S; Gunatilake S
    Acta Neuropsychiatr; 2004 Aug; 16(4):219-28. PubMed ID: 26984310
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neuroleptic malignant syndrome in a patient on long-term olanzapine treatment at a stable dose: Successful treatment with dantrolene.
    Kouparanis A; Bozikas A; Spilioti M; Tziomalos K
    Brain Inj; 2015; 29(5):658-60. PubMed ID: 25625410
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neuroleptic malignant syndrome.
    Rampertaap MP
    South Med J; 1986 Mar; 79(3):331-6. PubMed ID: 3513330
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neuroleptic malignant syndrome induced by atypical neuroleptics and responsive to lorazepam.
    Yacoub A; Francis A
    Neuropsychiatr Dis Treat; 2006 Jun; 2(2):235-40. PubMed ID: 19412469
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Catatonia and neuroleptic malignant syndrome in view of a psychopathological and pathophysiological overlap: a brief review].
    Asztalos Z; Egervári L; Andrássy G; Faludi G; Frecska E
    Neuropsychopharmacol Hung; 2014 Mar; 16(1):19-28. PubMed ID: 24687015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.